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Heart rateThe autonomic phenotype of congestive cardiac failure is characterised by high sympathetic drive and im-
paired vagal tone, which are independent predictors of mortality. We hypothesize that impaired bradycardia
to peripheral vagal stimulation following high-level sympathetic drive is due to sympatho-vagal crosstalk by
the adrenergic co-transmitters galanin and neuropeptide-Y (NPY). Moreover we hypothesize that galanin
acts similarly to NPY by reducing vagal acetylcholine release via a receptor mediated, protein kinase-
dependent pathway. Prolonged right stellate ganglion stimulation (10 Hz, 2 min, in the presence of 10 μM
metoprolol) in an isolated guinea pig atrial preparation with dual autonomic innervation leads to a signiﬁcant
(pb0.05) reduction in the magnitude of vagal bradycardia (5 Hz) maintained over the subsequent 20 min
(n=6). Immunohistochemistry demonstrated the presence of galanin in a small number of tyrosine hydrox-
ylase positive neurons from freshly dissected stellate ganglion tissue sections. Following 3 days of tissue cul-
ture however, most stellate neurons expressed galanin. Stellate stimulation caused the release of low levels of
galanin and signiﬁcantly higher levels of NPY into the surrounding perfusate (n=6, using ELISA). The reduc-
tion in vagal bradycardia post sympathetic stimulation was partially reversed by the galanin receptor antag-
onist M40 after 10 min (1 μM, n=5), and completely reversed with the NPY Y2 receptor antagonist BIIE 0246
at all time points (1 μM, n=6). Exogenous galanin (n=6, 50–500 nM) also reduced the heart rate response
to vagal stimulation but had no effect on the response to carbamylcholine that produced similar degrees of
bradycardia (n=6). Galanin (500 nM) also signiﬁcantly attenuated the release of 3H-acetylcholine from iso-
lated atria during ﬁeld stimulation (5 Hz, n=5). The effect of galanin on vagal bradycardia could be abolished
by the galanin receptor antagonist M40 (n=5). Importantly the GalR1 receptor was immunoﬂuorescently
co-localised with choline acetyl-transferase containing neurons at the sinoatrial node. The protein kinase C
inhibitor calphostin (100 nM, n=6) abolished the effect of galanin on vagal bradycardia whilst the protein
kinase A inhibitor H89 (500 nM, n=6) had no effect. These results demonstrate that prolonged sympathetic
activation releases the slowly diffusing adrenergic co-transmitter galanin in addition to NPY, and that this
contributes to the attenuation in vagal bradycardia via a reduction in acetylcholine release. This effect is me-
diated by GalR1 receptors on vagal neurons coupled to protein kinase C dependent signalling pathways. The
role of galanin may become more important following an acute injury response where galanin expression is
increased.
© 2011 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Sympathetic neurons throughout the autonomic nervous system
contain co-transmitters such as ATP, neuropeptide-Y and galanin, in ad-
dition to the main neurotransmitter norepineprhine [1–3]. The release
of co-transmitters is highly dependent on the level of neuronal stimula-
tion, and they tend to be slowly diffusing molecules that often functioning).
-NC-ND license. as neuromodulators rather than classical neurotransmitters [3]. High-
level cardiac sympathetic stimulation in the presence of beta-adrenergic
blockade is associatedwith reduced chronotropic responses to peripheral
stimulation of the right cardiac vagus nerve [4,5]. One possibility is that
sympathetic co-transmitters are responsible for this phenomenon by
acting locally within the heart at the site of cholinergic neurons to re-
duce acetylcholine release, and thus contribute to a potentially pro-
arrhythmic shift in autonomic balance [6]. High cardiac sympathetic
drive with reduced vagal tone is the characteristic autonomic pheno-
type associated with myocardial infarction and congestive heart failure
and is a poor prognostic indicator (e.g. [7–10]). Interestingly, elevated
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conditions where levels also correlate with mortality [11–13].
Whilst others have shown that adrenergic or purinergic receptor
stimulation is unable to alter cardiac acetylcholine release in humans
[14] or guinea pigs [15,16], we have recently reported direct evidence
showing how neuropeptide-Y inhibits cardiac acetylcholine release
and vagal bradycardia via Y2 receptors on cholinergic neurons which
couple to protein kinase C dependent signalling pathways [17]. More-
over, the Y2 receptor antagonist BIIE 0246 also partially reverses im-
paired heart rate responsiveness by the cardiac vagus after prolonged
sympathetic stimulation in-vivo [in the mouse [18], and dog [19]] dur-
ing which neuropeptide-Y release has been directly measured [in the
dog [20]]. Genetic knockout of the Y2 receptor has similar effects to
BIIE 0246 [21].
The neuropeptide co-transmitter galanin is known to be involved in
the central regulation of the cardiovascular system at the level of the
brainstem and, alongwith related peptides, may also act as a vasoactive
substance in the vasculature (see [22] for a review). Interestingly,
knockout of the galanin GalR1 receptor also partially prevents the im-
paired vagal bradycardia post peripheral sympathetic stimulation in
the mouse [4,18]. The cardiac release of galanin in these conditions has
not been demonstrated however, and the mechanism behind the ef-
fect of GalR1 gene knockout is unclear. We therefore hypothesized
that galanin is expressed in tyrosine hydroxylase positive neurons
of the stellate ganglion and is released upon high frequency sympa-
thetic stimulation in an isolated guinea pig sinoatrial node prepara-
tion with intact right stellate and vagal innervation. Moreover, we
hypothesize that galanin receptors are located on cholinergic neu-
rons that innervate the sinoatrial node, and that endogenously re-
leased or exogenously applied galanin reduces vagal bradycardia
via a GalR1 receptor mediated pathway. We also investigated if gala-
nin acts similarly to neuropeptide-Y by inhibiting acetylcholine re-
lease via a protein kinase dependent pathway.
2. Methods
Experiments conformed to the Guide for the Care and Use of Labora-
tory Animals published by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996) and the Animals (Scientiﬁc Proce-
dures) Act 1986 (UK). Adult (300–400 g, n=90) female guinea pigs
(Cavia porcellus, Dunkin Hartley) were killed by cervical dislocation
and exsanguinated according to Schedule 1. Experiments were per-
formed under British Home Ofﬁce Project License PPL 30/2130 and
PPL 30/2630.
2.1. Immunohistochemistry
The midbrain, right atria and stellate ganglia were dissected free
(n=6 animals) and placed in separate vials containing fresh ﬁxative
(2% paraformaldehyde containing 0.2% picric acid) over night and then
placed in 0.1 M phosphate-buffered saline (PBS) containing 20% sucrose
for cyroprotection until sectioned. Tissue sections (20 μmstellate, 40 μm
right atria and guinea pig midbrain)were processed by direct mounting
techniques as described previously [23,24]. In a separate set of experi-
ments stellate neurons were dissociated and maintained in culture
media for 3 days as described in detail previously [25–27] prior to a
1 hour exposure toﬁxative (2% paraformaldehyde containing 0.2% picric
acid). The ﬁxed tissue sections or dissociated cells were rinsed in PBS,
permeabilized with 0.5% Triton X-100, and incubated at 4 °C overnight
with a primary antiserum directed against tyrosine hydroxylase (TH)
(mousemonoclonal 1:400 fromRBI, NatickMA) and a primary antiserum
against galanin (rabbit polyclonal 1:1000 from Phoenix Pharmaceuticals,
Burlingame CA). Following removal of the primary antisera, the ganglion
sections/dissociated cells were incubated for 1 h at room temperature
with ﬂuorescein isothiocyanate (FITC)-conjugated or indocarbocyanine(Cy3)-conjugated secondary antiserum (Jackson Immunoresearch Lab-
oratories, west Grove, PA, 1:100 and 1:500 respectively).
The whole-mount stellate preparations and dissociated neurons
were viewedwith anOlympusAX70ﬂuorescencemicroscope equipped
withHBO 100-WUV light source and ﬁlters for FITC and Cy3. Digital im-
ageswere obtained with a CCD camera (MagnaFire SP; Optronics; Opti-
cal Analysis Corp., Nashua, NH) and imported into Adobe Photoshop
CS3 (Adobe Corporation, Mountain View, CA) to assemble ﬁgures,
which were minimally adjusted for contrast and brightness. Both anti-
sera used are well characterised and have been employed in prior stud-
ies (e.g. [28]). In addition, neuronal staining was not observed when
whole mounts were treated only with secondary antiserum.
Fixed right atrial slices (or guinea pig midbrain as a positive control)
were incubated with rabbit anti-GalR1 (Sigma, 1:200), anti-GalR2 (Afﬁn-
ity Bioreagents, 1:150) or anti-GalR3 (Sigma, 1:150) primary antibodies
followed by biotinylated goat anti-rabbit (Vector, 1:200). Conjugation
was then performed using a ﬂuorescein stain followed by blocking of
remaining unbound biotin with a Streptavidin Biotin Blocking Kit. To as-
sess galanin receptor–choline acetyltransferase (ChAT) co-localization,
neurons were further labelled with goat anti-ChAT (Vector, 1:200), fol-
lowed by secondary, biotinylated horse anti-goat (Vector, 1:200). Conju-
gation was then performed using a Texas Red stain. Images were
obtained using a Nikon Eclipse TE2000-U inversion ﬂuorescent light mi-
croscope and appropriate ﬁlters (560/40 nmTexas Red and 460–500 nm
ﬂuorescein ﬁlters). Neuronal staining was not observed when whole
mounts were treated only with secondary antiserum.
2.2. Reverse transcription-polymerase chain reaction
Stellate ganglia, cardiac ganglia and brain were dissected (n=3 an-
imals) under RNase-free conditions and total RNA was extracted from
individual preparations using Tri reagent (Sigma) as described previ-
ously [29]. The total RNA quantity for each whole-mount preparation
was determined with a Nanodrop ND-1000 spectrophotometer (Nano-
drop Technologies, Wilmington, DE). One microgram of RNA per sam-
ple was used to synthesize complementary DNA with the Omniscript
reverse transcription (Qiagen, Valencia, CA) and a mix of oligo-dT and
random hexamer primers. Ampliﬁed MPG DNA product from speciﬁc
primers was ligated into pCR2.1 TOPO using TOPO TA cloning kit (Invi-
trogen, Carlsbad, CA) to generate plasmid standards. The nucleotide se-
quences of the inserts were veriﬁed by automated ﬂuorescent dideoxy
dye terminator sequencing (Vermont Cancer Center DNAAnalysis Facil-
ity), and ten-fold serial dilutions of stock plasmidwere prepared to gen-
erate assay standard curves. Ampliﬁcation of the cDNA templates and
plasmid standards was performed using HotStart IT® SYBR® Green
qPCR Master Mix (USB). Real-time quantitative PCR was performed
on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Nor-
walk, CT).
The primers (designed using the Ensembl sequence) and conditions
used were: Galanin: (+)TCCTGCTCCTCTCGCTCC, (−)CTTCTCCTTTGCCG-
GGAA; 53 °C for 30 s; GALR1: (+)ACTTTATCACGCTGGTGGTGTTTG, (−)
ACCGTGAAGACATAGTGGGTGAA; 60 °C for 30 s; GALR2: (+)ACTTCCT-
CATCTTCCTCACCA, (−)TGCCAGCGCGTTTCGAG; 54 °C for 30 s; GALR3:
(+)AGGGAGTGTGGGGGCTGTG, (−)AAGAGCCAGGCATCCAGCGT; 62 °C
for 30 s.
2.3. Isolated sinoatrial node/right stellate ganglion/right vagus nerve
preparation
The spontaneously beating atria with intact right stellate ganglion
and right vagus nerve were isolated (n=70 animals) and transferred
to a preheated (37±0.2 °C), continuously oxygenated, water-jacketed
organ bath containing 60 ml Tyrode solution. Themethod for dissecting
and measuring responses to nerve stimulation has been described pre-
viously [17]. Before starting each protocol, the mounted atria were
allowed to equilibrate for 80 min until beating rate stabilized (±5
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organ bath was replaced approximately every 30 min throughout
each protocol. The vagus was stimulated at 1, 3, and 5 Hz, (20 V, 1 ms
pulse duration for 30 s) before and after high level stimulation of the
right stellate ganglion via ring electrodes placed around the ganglion it-
self (at 10 Hz, 20 V, 1 ms pulse duration for 2 min) and/or application of
drugs to the organ bath. This level of sympathetic stimulation was cho-
sen as it has previously been shown to reduce the heart rate response to
peripheral vagal stimulation in-vivo and cause release of neuropeptide-
Y [5,20]. These frequencies were chosen to produce physiological de-
grees of bradycardia from thebaselineheart rate of up to 30–40%. A con-
trol experiment showed that the heart rate response to vagal nerve
stimulation remained constant (±1 bpm at 5 Hz) over a two-hour peri-
od. We have previously shown that all heart rate changes from vagal
nerve stimulation are completely abolished by hyoscine in this prepara-
tion and are therefore due to release of acetylcholine [30].
2.4. Measuring galanin and neuropeptide-Y release to sympathetic stim-
ulation from isolated guinea pig right atrial preparations
The spontaneously beating right atriumwas isolated (n=6 animals)
and transferred to a preheated (37±0.2 °C), continuously oxygenated,
water-jacketed organ bath containing 2 ml Tyrode solution where the
atrium was pinned ﬂat on a silver stimulating electrode. After an equil-
ibration period of 30 min, the Tyrode solutionwas changed and the stel-
late stimulated at 10 Hz (20 V, 1 ms pulse duration for 2 min). 50 μl
samples of perfusate were taken from the bath 5, 10, 15 and 20 min be-
fore and after sympathetic stimulation and neuropeptide-Y or galanin
concentrations measured using commercially available ELISA based as-
says (S1346 neuropeptide-Y, and S1347 galanin, Penninsular Laborato-
ries, Bachem) against serially diluted protein standards.
2.5. Measuring 3H-acetylcholine release to ﬁeld stimulation from isolated
guinea pig right atrial preparations
The spontaneously beating right atrium was isolated (n=5 ani-
mals) and transferred to a preheated (37±0.2 °C), continuously oxy-
genated, water-jacketed organ bath containing 3 ml Tyrode solution
where the atrium was pinned ﬂat on a silver stimulating electrode.
The method for determining the local release of 3H-acetylcholine to
ﬁeld stimulation at 5 Hz (20 V, 1 ms pulse width, for 1 min) after in-
cubation with 3H-choline chloride (10 μCi, Amersham U.K.) and
washing, was identical to that which we have previously described
[17].
2.6. Solutions and drugs
The Tyrode solution contained (mM) NaCl 120, KCl 4, MgCl2 2,
NaHCO3 25, CaCl2 2, Na2HPO4 0.1 and glucose 11. The solution was
aerated with 95% O2/5% CO2 (pH 7.4) and its temperature was contin-
uously monitored (Digitron 1408-K gauge) and kept at 37±0.2 °C.
The effect of prolonged, high frequency right stellate stimulation
was compared to that of bath applied ephrine (10 μM, Sigma) at a
dose that produced a similar degree of tachycardia with or without
beta-adrenergic blockade using metoprolol (10 μM, Sigma). Galanin
(1–29, Bachem)was used in concentrations of up to 500 nM. The effect
of sympathetic nerve stimulation or galanin on the heart rate response
to vagal nerve stimulationwas compared to those of the stable analogue
of acetylcholine carbamylcholine (90 nM, Sigma) to determinewhether
the effects were pre or postsynaptic. This concentration was chosen to
produce similar degrees of bradycardia to 5 Hz vagal nerve stimulation.
M40 (1 μM, Tocris) was used as a selective galanin receptor antagonist
and BIIE 0246 (1 μM, Tocris) as a selective antagonist of the Y2 receptor.
Protein kinase A was inhibited using H89 (0.5 μM, Calbiochem) and
protein kinase C using Calphostin C (0.1 μM, Calbiochem). The concen-
trations chosen are above the reported Ki for the isolated enzymes(0.007 μM M40 for the GalR1 receptor [31], 0.02 μM BIIE 0246 for the
Y2 receptor [32], 0.05 μM Calphostin C for PKC [33], and 0.05 μM H-89
for PKA [34]) but below those reported for non-speciﬁc actions of the
drugs. They are the same as those previously used in similar prepara-
tions (e.g. [35] for M40, [17] for BIIE 0246, H89, and Calphostin C).
Drugs were dissolved in reagent grade water from an Elga puriﬁ-
cation system except Calphostin C, and H-89 that were dissolved in
Dimethylsulfoxide (DMSO). A control experiment showed that DMSO
at the concentrations used did not affect the heart rate response to
vagal nerve stimulation at 1, 3 or 5 Hz.
2.7. Statistical analysis
Data are presented as mean±S.E.M, and all data passed a normality
test. The “n” number refers to the number of separate animals used and
only one protocol was carried out on any preparation from a particular
animal. One-way repeatedmeasures ANOVAwas used to evaluate the ef-
fect of an intervention. An unpaired student's t-test assuming unequal
variance was used to evaluate signiﬁcance between two independent ex-
perimental groups. Statistical signiﬁcance was accepted at pb0.05 and
was not affected by analyzing the data in terms of heart rate changes or
change in pulse interval. Analyzing the data from the 3H-acetylcholine re-
lease experiments in terms of the absolute increase in 3H efﬂux to ﬁeld
stimulations S1 and S2, or the ratio between the two responses (S2/S1)
did not change statistical signiﬁcance.
3. Results
3.1. Galanin expression in stellate ganglia and galanin receptors on right
atrial cholinergic neurons
RT-PCR from right and left stellate ganglia conﬁrmed the presence
of low levels of galaninmRNA. Immunohistochemistry of freshly ﬁxed
right and left stellate ganglia from 2 animals showed galanin staining
in a small proportion (b5%) of tyrosine hydroxylase positive neurons
(Fig. 1B). In these cells the ﬂuorescence was brighter than back-
ground and granular in appearance. However, when the stellate neu-
rons were dissociated and kept in culture for 3 days, nearly all the
neurons exhibited immunoreactivity for both tyrosine hydroxylase
(Fig. 1C left panel) and galanin (Fig. 1C right panel).
RT-PCR from intrinsic cardiac ganglia demonstrated the presence of
mRNA for both the GalR1 and GalR3 receptors (Fig. 1D). However, im-
munohistochemistry showed staining for the GalR1 receptor only in
right atrial slices (Fig. 1E) localised in neuronal structures (see magni-
ﬁed inset). Co-stainingwith ChAT showedGalR1 localised to cholinergic
neurons only (Fig. 1F). This provides the anatomical basis for our hy-
pothesis that galanin released from sympathetic neurons may alter
vagal control of heart rate.
3.2. Vagal bradycardia post sympathetic stimulation and endogenous
galanin and neuropeptide-Y release
After the equilibration period baseline heart rate in isolated sinoatri-
al node/dual autonomic innervation preparation was 190±3 bpm
(n=70) and did not change signiﬁcantly with the pharmacological in-
terventions used unless stated. As can be seen in Fig. 2 (black lines), fol-
lowing 2 min of high frequency sympathetic stimulation in the
presence ofmetoprolol, the heart rate response to vagal stimulation sig-
niﬁcantly reduced over the subsequent 20 min to 71±5% of its starting
value (baseline heart rate 187±9 bpm, n=6). This was not observed
when norepinephrine (10 μM)was used rather than sympathetic stim-
ulation where the heart rate response to vagal nerve stimulation
remained at 114±12% of its original starting value after 20 min (base-
line heart rate: 187±7 bpm, n=5). In addition, the heart rate response
to the stable analogue of acetylcholine, carbamylcholine (90 nM)which
produces similar degrees of bradycardia as vagal nerve stimulation at
Gal R1 ChAT Co-localizationLight microscopy
Gal R1
GP atria
GP midbrain 
Gal R2 Gal R3
A
D E
F
Sympathetic neurons from the stellate ganglia 
Cardiac post-ganglionic vagal neurons
La
dd
er
Br
ai
n
R
ig
ht
 s
te
lla
te
Le
ft 
st
el
la
te
NT
C
74 bp Galanin
TH Galanin
GalaninTH
Stellate sections
Cultured neurons
B
C
Fig. 1. Expression of galanin in stellate sympathetic neurons and GalR1 on cardiac cholinergic neurons. (A) Reverse transcription-polymerase chain reaction (RT-PCR) products
viewed on an ethidium bromide gel after ampliﬁcation of freshly dissected stellate ganglia and brain mRNA. NTC, no template control, is a negative control assessing the absence
of contamination. Galanin mRNA is present in both right and left stellate ganglia. (B) All stellate neurons from freshly dissected left and right stellate ganglia exhibit immunoreac-
tivity for tyrosine hydroxylase (TH, left panel, 20 μm sections) but only occasionally do TH immunoreactive neurons also exhibit galanin immunoreactivity (b5%, right panel, cal-
ibration bar=20 μm). (C) Dissociated stellate neurons cultured for 3-days exhibit immunoreactivity for TH (left hand panel) and galanin (right hand panel, calibration
bar=20 μm). (D) RT-PCR bands for the galanin receptors GalR1 (253 base pairs) and GalR3 (234 base pairs) from mRNA isolated from cardiac ganglia. Guinea pig brain was
used as a positive control, and reaction mix without template was the negative control (NTC). (E) Immunohistochemistry of right atrial slices showing expression of GalR1 receptor
protein in neuronal structures only (see inset picture at higher magniﬁcation, calibration bar=10 μm). GalR1, GalR2 and GalR3 expression was demonstrated in guinea pig midbrain
as a positive control (calibration bar=20 μm). (F) Immunohistochemistry showing choline acetyltransferase (ChAT) staining with Texas Red in a neuron in right atrial slices also
staining positive for the galanin GalR1 receptor in green (ﬂuorescein). Co-localization was demonstrated by overlap of staining in yellow (calibration bar=20 μm).
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ulation remaining at 97±6% of its starting value after 20 min (baseline
heart rate 198±8 bpm, n=6). In each of these protocols the change in
baseline heart rate during sympathetic stimulation or addition of nor-
epinephrine in the presence of metoprolol was similar (sympathetic
stimulation following by vagal nerve stimulation +14±4%; norepi-
nephrine followed by vagal nerve stimulation +15±4%; sympathetic
nerve stimulation followed by carbamylcholine +16±8%). Thissuggests that released substances other than norepinephrine are acting
pre-synaptically to alter vagal neurotransmission and cause a reduction
in vagal bradycardia following high frequency sympathetic nerve
stimulation.
To test the hypothesis that such released substances may include
the co-transmitters neuropeptide-Y or galanin, the heart rate re-
sponse to vagal nerve stimulation post high frequency sympathetic
stimulation was assessed in the presence of the neuropeptide-Y Y2
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Fig. 2. Release of co-transmitters after high frequency sympathetic stimulation and the corresponding reduction in vagal bradycardia. Representative raw data traces (A and D) and
group mean data (B and E) showing the heart rate response to vagal nerve stimulation (5 Hz, 30 s) before and during the 20 minute period after high frequency stimulation of the
right stellate ganglion (SNS, 10 Hz, 2 min, in the presence of 10 μM metoprolol). A control experiment is shown in black (baseline heart rate 187±9 bpm, n=6), whilst in a sep-
arate set of experiments shown in blue (A and B), this was repeated in the presence of the neuropeptide-Y receptor antagonist BIIE 0246 (1 μM, baseline heart rate 180±9 bpm,
n=6) and in a further set of experiments shown in red (D and E) this was repeated in the presence of the galanin GalR1 receptor antagonist M40 (1 μM, baseline heart rate 183±
pre-stimulation was not signiﬁcantly different to that using sympathetic pre-stimulation in the presence of BIIE 0246 (data not shown). C and F show the organ bath concentrations
of neuropeptide-Y (n=6, blue) and galanin (n=6, red) before and during the 20 min after high frequency sympathetic nerve stimulation (10 Hz, 2 min in the presence of meto-
prolol 10 μM) measured in 50 μl organ bath samples analysed using ELISA. (*pb0.05 vs control).
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As can be seen in Figs. 2A and B (blue traces), BIIE 0246 prevented the
reduction in vagal bradycardia at all time points, mimicking the pattern
of responses observed following norepinephrine pre-stimulation rather
than sympathetic nerve stimulation (baseline heart rate 180±9 bpm,
n=6). Figs. 2D and E demonstrates the effect of M40 (red traces).
M40 only prevented the reduction in vagal bradycardia post sympathet-
ic stimulation at 10 min and beyond (baseline heart rate 183±13 bpm,
n=5). Release of both neuropeptide-Y and galanin could be detected in
the perfusate surrounding the sinoatrial node/right stellate ganglion
preparation at all time points following high frequency sympatheticstimulation (see Figs. 2C and F). Signiﬁcantly more neuropeptide-Y
was released compared to galanin after 15 and 20 min however. The
maximum concentration of peptide released was 0.124±0.03 ng/ml
(0.03±0.01 nM) neuropeptide-Y (n=6), and 0.054±0.012 ng/ml
(0.02±0.01 nM) galanin (n=6) whereas the control peptide concen-
trationswere below the detection level of the assays prior to sympathet-
ic stimulation (b0.001 ng/ml).
We have previously shown that exogenous neuropeptide-Y can
reduce vagal bradycardia and acetylcholine release at concentrations
of 100 nM and above [17]. As can be seen in Fig. 3, exogenous galanin
also signiﬁcantly reduced vagal bradycardia at 50 nM at 1 Hz and at
672 N. Herring et al. / Journal of Molecular and Cellular Cardiology 52 (2012) 667–676all stimulation frequencies at 100 nM and above, although there was a
trend to reduce vagal bradycardia even at 5–10 nM. The effect of galanin
could be partially reversed with wash off of the peptide (baseline heart
rate 192±14 bpm, control 5 Hz−72±6 bpm, 500 nM galanin−36±
10 bpm, wash off −53±9 bpm, control 3 Hz −40±6 bpm, 500 nM
galanin −17±5 bpm, wash off −34±6, control 1 Hz −11±1 bpm,
500 nM galanin−4±1 bpm, wash off−9±3, n=6).
The GalR receptor antagonist M40 also prevented exogenous gala-
nin (100 and 250 nM) from reducing the heart rate response to vagal
nerve stimulation (baseline heart rate 200±6 bpm, n=5) whilst the
neuropeptide-Y receptor antagonist BIIE 0246 did not prevent galanin
from reducing vagal bradycardia at the same concentrations (baseline
heart rate 169±12 bpm, n=5) as can be seen in Fig. 4. Conversely,
the reduction in vagal bradycardia to exogenous neuropeptide-Y
was not prevented by M40 (e.g. baseline heart rate 174±1 bpm, 5 Hz
control −64±4 bpm, 1 μM M40 −52±4 bpm, 250 nM neuropeptide-
Y−40±4 bpm, n=4).
3.3. Galanin attenuates vagal bradycardia via a pre-synaptic pathway to
reduce acetylcholine release
Whilst galanin signiﬁcantly reduced the heart rate response to
vagus nerve stimulation at 5 Hz (see Fig. 5A at 500 nM, baseline
heart rate 192±14 bpm, n=6), the heart rate response to 90 nM car-
bamylcholine, which produced similar degrees of bradycardia, was
not affected by galanin (see Fig. 5B at 500 nM, baseline heart rate
190±9 bpm, n=6). This suggests that galanin acts pre-synaptically
to modulate parasympathetic neurotransmission. To test this hypoth-
esis directly, we demonstrated that the same concentration of galanin
(500 nM) signiﬁcantly reduced the release of 3H-acetylcholine in re-
sponse to ﬁeld stimulation at 5 Hz in isolated atria (see Fig. 5C,
n=5). A time control experiment demonstrates no run down of 3H-
acetylcholine release over the two stimulations [17].
To investigate the second messenger pathway that couples
galanin-induced inhibition of vagal bradycardia via GalR1 to a reduc-
tion in acetylcholine release, we assessed the effect of galanin in theControl 5 10
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tion of the right vagus nerve (5, 3 or 1 Hz, for 30 s) in the presence of increasing
concentrations of galanin (5–500 nM). (*pb0.05 vs control).presence of the protein kinase A inhibitor H89 and the protein kinase
C inhibitor calphostin C. Whilst galanin (at 100 and 250 nM)was still
able to reduce vagal bradycardia in the presence of H89 (baseline
heart rate 204±9 bpm, n=6), the same concentrations of galanin
were unable to reduce vagal bradycardia in the presence of calphos-
tin C (baseline heart rate 207±3 bpm, n=6) as can be seen in Fig. 6
suggesting that galanin is acting via a protein kinase C dependent
pathway.
4. Discussion
The main new ﬁndings of this study are as follows.
First, galanin is expressed in a small number of tyrosine hydroxylase
positive neurons of the guinea pig stellate ganglion but can be found in
most stellate neurons following tissue culture for 3 days, which may
represent an acute injury response.
Secondly, galanin is released on high frequency sympathetic stim-
ulation along with neuropeptide-Y, and the reduction in vagal brady-
cardia post high frequency sympathetic stimulation (in the presence
of beta-blockade) is partly reversed by a galanin receptor antagonist
and completely reversed by a neuropeptide-Y Y2 receptor antagonist.
Thirdly, the GalR1 receptor is localised on intrinsic cholinergic
neurons at the sinoatrial node. Like neuropeptide-Y, exogenous gala-
nin reduces vagal bradycardia via a pre-synaptic pathway involving a
reduction in acetylcholine release that is GalR1 receptor mediated and
protein kinase C dependent.
Finally, there does not appear to be any cross reactivity between
neuropeptide-Y and galanin in terms of their respective membrane
receptors as Y2 receptor inhibition does not alter the inhibitory action
of galanin and GalR1 inhibition does not alter the inhibitory action of
neuropeptide-Y.
4.1. Sympathovagal cross-talk by adrenergic co-transmitters
We demonstrated that sympathetic neurons from freshly dissect-
ed left and right stellate ganglia contain mRNA for galanin although
b5% of the total number of neurons express the protein. Others
have also shown galanin immunoreactivity in intact stellate ganglia
both in nerve ﬁbres and a small number of small intensely ﬂuorescent
cells of the guinea pig stellate [36], although without co-staining for
tyrosine hydroxylase. However, following dissociation and 3 days of
culture, most sympathetic neurons from both ganglia express galanin.
This is an interesting ﬁnding and may represent an injury response as
local cardiac galanin expression is also increased in a rat model post
myocardial infarction [37] driven by sympathetic hyperactivity [38].
Whether excess galanin production contributes to impaired vagal
neurotransmission in this context remains to be shown.
We also demonstrated the release of both neuropeptide-Y and
galanin into the tissue perfusate following sympathetic stimulation,
however signiﬁcantly more neuropeptide-Y was released than gala-
nin. The peak perfusate concentrations (20–30 pM over 20 min post
2 minute sympathetic stimulation) were signiﬁcantly less than the
concentrations of exogenous peptide required to signiﬁcantly reduce
vagal bradycardia (50 nM and above, over a 10 min incubation peri-
od, although there was a trend for a reduction in vagal bradycardia
even at the lowest 5 nM dose used) as is observed with many neuro-
transmitters and bioassays. Given localised metabolism, re-uptake
and diffusion, neither are likely to accurately reﬂect the exact concen-
tration of peptide released locally at the level of the neuronwithin the
atrial tissue. Instead, the dose response curve experiments should be
viewed as proof of principle that exogenous galanin can reduce vagal
bradycardia.
Our perfusate concentrationswere higher than thosemean values ob-
served in human plasma (e.g. galanin 4–6 pM [39], neuropeptide-Y
18 pM [40]) but lower than those of neuropeptide-Y collected from cor-
onary venous sinus blood sampling immediately after cardiac
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stimulation at 10 Hz [20]). Perfusate protein levels unsurprisingly steadi-
ly rose in our static organ bath preparation over a 20-minute period. The
dynamics of release and vagal responsiveness in our preparation are un-
likely to accurately reﬂect the exact time course observed in-vivo. For ex-
ample, coronary venous sinus levels of neuropeptide-Y and vagal
inhibition post sympathetic stimulation peaked inside 10 min and then
were observed to fall in the hour following sympathetic stimulation in-
vivo [20]. Importantly we demonstrated that the reduction in vagal bra-
dycardia post sympathetic stimulation was reversed at all time points
by a Y2 receptor antagonist and at 10 min and beyond by aGalR1 receptor
antagonist. Moreover we have demonstrated that these receptor antago-
nists inhibit the effects of their corresponding peptidewhilst not affecting
the response to the other peptide. This provides convincing evidence that
neuropeptide-Y and galanin contribute to the reduction in vagal brady-
cardia post sympathetic stimulation although the action of both peptides
is not essential for this to occur.
Exogenous galaninmay reduce the heart rate response to peripheral
stimulation of the right vagus nerve in themouse [4,18] and cat [41] in-
vivo, but this was not observed in the rat [42] or dog [43]. Systemic in-
fusion of neuropeptides in-vivo is also complicated bypotential changes
in haemodynamics and other circulating factors complicating the inter-
pretation of data. Interestingly, galanin has been identiﬁed in human
plasma and its levels rise following exercise [44] and during head up
tilt table testing of patients with vasovagal syncopy as blood pressure
and heart rate increase. Indeed intravenous administration of galanin
increases resting heart rate in humans [45,46] associated with the abo-
lition of sinus arrhythmia [45]. Galanin infusion also prevents the bra-
dycardia secondary to the cholinesterase inhibitor pyridostigmine in
humans [47] suggesting a vagal site of action, but to our knowledge
this is the ﬁrst direct evidence that galanin is released during cardiacsympathetic hyper-activity and that it directly inhibits cholinergic
neurotransmission.
We also observed a small increase in the magnitude of the vagal
bradycardia after 5 min in the presence of norepinephrine (to 122±
13% of control), or following sympathetic nerve stimulation following
Y2 receptor inhibition (to 123±7% of control). This was likely to be
related to the small increase in baseline heart rate despite beta-
blockade and post-synaptic accentuated antagonism. For example
the heart rate response to vagal nerve stimulation (5 Hz) post sympa-
thetic stimulation (10 Hz for 2 min) in the absence of a beta-blocker
increased to 168±21% from control where baseline heart rate in-
creased by 70±11% (n=4). Similar observations were made using
norepinephrine and carbamylcholine.
4.2. Mechanism of action of galanin on vagal function
We clearly demonstrated that exogenous galanin inhibits the
heart rate response to peripheral vagal nerve stimulation via a pre-
synaptic mechanism. Moreover, galanin inhibits the evoked release
of 3H-acetylcholine in response to ﬁeld stimulation at the same fre-
quency of stimulation and at the same dose. After loading right atrial
neuronal stores with 3H-choline, measuring the increase in radioac-
tivity efﬂux to ﬁeld stimulation has been taken to represent acetyl-
choline release arising mainly from post-ganglionic vagal neurons.
The increase in organ bath radioactivity during ﬁeld stimulation is
prevented by removal of extracellular calcium and can be inhibited
by N-type calcium channel blockers [48,49]. However, it is not clear
how much 3H-acetylcholine release arises from the pre-ganglionic–
post-ganglionic synapse. We have tried to stimulate post-ganglionic
neuronal nicotinic receptors using a variety of nicotinic agonists but
they produced very small degrees of bradycardia (even in the
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Fig. 7. Cardiac sympatho-vagal crosstalk by adrenergic co-transmitters. A diagram hy-
pothesizing the mechanism by which the adrenergic co-transmitters neuropeptide-Y
(NPY, red square) and galanin (Gal, red square) are released during high frequency
sympathetic stimulation in the presence of beta blockade (norepinephrine, NE, black
circle, and metoprolol, yellow cross). Neuropeptide-Y and galanin act via the Y2 and
GalR1 receptors respectively to reduce acetylcholine (ACh, black triangle) release and
subsequent vagal bradycardia at the sinoatrial node. Both GalR1 and Y2 receptor signal-
ling directly or indirectly involves protein kinase C (PKC).
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vagus stimulation or muscarinic agonists. Further attenuation of
such small responses would be difﬁcult to detect making it hard to
draw clear conclusions regarding the exact site of action of galanin
by this method. However, the immunochemical localisation of GalR1
to post-ganglionic cholinergic neurons strongly suggests that this is
the pre-synaptic site of action of galanin in our preparation.
We also demonstrated that protein kinase C inhibition prevents
the action of galanin of vagal bradycardia whilst protein kinase A in-
hibition had no effect. Neuromodulators such as neuronal nitric oxide
[50] and natriuretic peptides [51] increase acetylcholine release and
vagal bradycardia, and that this can be prevented by several different
protein kinase A inhibitors (including 0.5 μM H89). As observed previ-
ously, H89 and other protein kinase A inhibitors alone produce a small
but signiﬁcant reduction in vagal bradycardia [50] whilst phosphodies-
terase inhibition with milrinone increased acetylcholine release and
vagal bradycardia [50]. This suggests that there is a baseline level of
neuronal cAMP production increasing the gain of acetylcholine release.
We have also previously demonstrated that the inhibitory action of
neuropeptide-Y on acetylcholine release and vagal bradycardia was un-
affected by H89, but prevented by several different protein kinase C in-
hibitors (including 0.1 μM calphostin C) [17]. In keeping with this
hypothesis, the protein kinase C activator PMA can mimic the effect of
both neuropeptide-Y and galanin by inhibiting acetylcholine release
[17]. Importantly we also demonstrated that inhibition of the Y2 recep-
tor with BIIE 0246 did not prevent the action of galanin, whilst inhibi-
tion of GalR1 with M40 does not prevent the action of neuropeptide-Y.
This supports the notion that the two co-transmitter signalling path-
ways integrate at the level of the secondmessenger rather than by shar-
ing similar membrane receptors.
Neuropeptide-Y and galanin may signal directly through the IP3/
DAG–protein kinase C pathway, although both the Y2 [52] and GalR1
receptor [53] are traditionally thought to couple to Gαi. It is also pos-
sible that protein kinase C may be involved indirectly, for example
following a change in intracellular calcium handling to alter neuronal
excitability or the vesicular release mechanism itself. For example,
neuropeptide-Y increases outward potassium current in ventricular
myocytes via a pathway sensitive to both pertussis toxin and calphos-
tin C [54]. Conversely galanin has been shown to inhibit N-type calci-
um currents in mudpuppy cholinergic neurons [55]. It is difﬁcult to
investigate the role of G proteins experimentally in the preparation
used here as treatment with pertussis toxin ablates cholinergic medi-
ated bradycardia via a post-synaptic mechanism [56] (Fig. 7).4.3. Perspectives
Excessive adrenergic activity is a negative prognostic indicator post
myocardial infarction [8,9] and during congestive cardiac failure [7,10],
and has been implicated in both the aetiology and progression of hyper-
tension [57]. Under normal conditions the cardiac vagus nerve acts as
nature's beta-blocker, preventing intracellular calcium overload and
slowing heart rate. It can directly raise the threshold for induction of
ventricular ﬁbrillation [58]. Conditions that promote high vagal tone
[e.g. exercise training [59–61] and nNOS vagal gene transfer [24]] pro-
tect against mortality. It is possible that during myocardial infarction
and congestive heart failure where neuropeptide-Y plasma levels are
known to be elevated, both sympathetic co-transmitters are at least
partly responsible for reducing vagal activity. Local cardiac galanin ex-
pression is also increased in a rat model post myocardial infarction
[37], and this is driven by sympathetic hyperactivity [38]. If these co-
transmitters are responsible for impairing vagal function in pathological
conditions associated with high sympathetic drive, drugs targeted at
their receptors may provide additional beneﬁt when combined with
beta-blockers and ACE inhibitors, which target the sympatho-adrenal
axis alone.Funding
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